急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后无复流现象的治疗进展

doi:10.3969/j.issn.1674-490X.2023.03.006

摘要/Abstract

摘要： 急性ST段抬高型心肌梗死(acute ST-segment elevation myocardial infarction, STEMI)是世界范围内心血管疾病患者死亡的主要原因,及时开通相关动脉是最有效的治疗手段。通过经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)开通罪犯血管是急性STEMI的首选再灌注策略,然而,约半数患者PCI术后仍得不到充分的微循环灌注,出现无复流现象(no-reflow phenomenon, NRP),这与不良心血管事件的发生密切相关。现综述PCI术后NRP药物治疗和非药物治疗的研究进展。

关键词: 急性ST段抬高型心肌梗死, 经皮冠状动脉介入治疗, 无复流现象, 治疗进展

Abstract: Acute ST-segment elevation myocardial infarction(STEMI)is the cause of death for patients with cardiovascular disease worldwide, for which timely and effective opening of infarct related vessels is the most important treatment. Early restoration of culprit vessel patency by primary percutaneous coronary intervention(PCI)represents the reperfusion strategy of choice for patients with STEMI. However, about half of the patients still cannot get sufficient blood perfusion to the distal coronary microvasculature after PCI, which is closely related to the occurrence of adverse cardiovascular events. This situation is called no-reflow phenomenon(NRP). This article reviews recent treating progress of drug therapy and non-drug therapy for NRP after PCI.

Key words: acute ST-segment elevation myocardial infarction, percutaneous coronary intervention, no-reflow phenomenon, treatment progress

中图分类号:

范文甜,许亚欣,刘艺珂,陈春红. 急性ST段抬高型心肌梗死患者经皮冠状动脉介入治疗术后无复流现象的治疗进展[J]. 医学研究与教育, 2023, 40(3): 38-45.

参考文献

[1] 《中国心血管健康与疾病报告》编写组.《中国心血管健康与疾病报告2021》要点解读[J].中国心血管杂志, 2022, 27(4): 305-318. DOI: 10.3969/j.issn.1007-5410.2022.04.001.
[2] YANG L, CONG H L, LU Y L, et al. Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Medicine, 2020, 99(26): e20152. DOI: 10.1097/MD.0000000000020152.
[3] SOROP O, MERKUS D, DE BEER V J, et al. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis[J]. Circ Res, 2008, 102(7): 795-803. DOI: 10.1161/CIRCRESAHA.108.172528.
[4] KLONER R A, GANOTE C E, JENNINGS R B. The no-reflow phenomenon after temporary coronary occlusion in the dog[J]. J Clin Invest, 1974, 54(6): 1496-1508. DOI: 10.1172/JCI107898.
[5] HAUSENLOY D J, CHILIAN W, CREA F, et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection[J]. Cardiovasc Res, 2019, 115(7): 1143-1155. DOI: 10.1093/cvr/cvy286.
[6] LE D E, ZHAO Y, KAUL S. Persistent coronary vasomotor tone during myocardial ischemia occurs at the capillary level and may involve pericytes[J]. Front Cardiovasc Med, 2022, 9: 930492. DOI: 10.3389/fcvm.2022.930492.
[7] YU H, KALOGERIS T, KORTHUIS R J. Reactive species-induced microvascular dysfunction in ischemia/reperfusion[J]. Free Radic Biol Med, 2019, 135: 182-197. DOI: 10.1016/j.freeradbiomed.2019.02.031.
[8] KATAYAMA Y, TARUYA A, KASHIWAGI M, et al. No-reflow phenomenon and in vivo cholesterol crystals combined with lipid core in acute myocardial infarction[J]. Int J Cardiol Heart Vasc, 2022, 38: 100953. DOI: 10.1016/j.ijcha.2022.100953.
[9] RIKSEN N P, FRANKE B, VAN DEN BROEK P, et al. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo[J]. Pharmacogenetics Genom, 2007, 17(7): 551-554. DOI: 10.1097/fpc.0b013e32803fb78f.
[10] KONIJNENBERG L S F, DAMMAN P, DUNCKER D J, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction[J]. Cardiovasc Res, 2020, 116(4): 787-805. DOI: 10.1093/cvr/cvz301.
[11] HUANG X, ZHENG W, ZHAO X D, et al. CHA₂DS₂-VASc score predicts the slow flow/no-reflow phenomenon in ST-segment elevation myocardial infarction patients with multivessel disease undergoing primary percutaneous coronary intervention[J]. Medicine, 2021, 100(21): e26162. DOI: 10.1097/MD.0000000000026162.
[12] A?瘙塁KIN L, AKTÜRK E. Association between SYNTAX II score and electrocardiographic evidence of no-reflow in patients with ST-segment elevation myocardial infarction[J]. Turk Kardiyol Dern Ars, 2018, 46(6): 455-463. DOI: 10.5543/tkda.2018.86132.
[13] WANG Z Y, REN L H, LIU N, et al. Utility of hematological parameters in predicting No-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Clin Appl Thromb Hemost, 2018, 24(7): 1177-1183. DOI: 10.1177/1076029618761005.
[14] ZHANG Q Y, HU M R, SUN J Y, et al. The combination of neutrophil-to-lymphocyte ratio and platelet correlation parameters in predicting the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction[J]. Scand Cardiovasc J, 2020, 54(6): 352-357. DOI: 10.1080/14017431.2020.1783457.
[15] EITEL I, NOWAK M, STEHL C, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging[J]. Am Heart J, 2010, 159(5): 882-890. DOI: 10.1016/j.ahj.2010.02.019.
[16] KHALFALLAH M, MARIA D A, ALLAITHY A. Impact of stress hyperglycemia on No-reflow phenomenon in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Glob Heart, 2022, 17(1): 23. DOI: 10.5334/gh.1111.
[17] GARCÍA-PRIETO J, VILLENA-GUTIÉRREZ R, GÓMEZ M, et al. Neutrophil stunning by metoprolol reduces infarct size[J]. Nat Commun, 2017, 8: 14780. DOI: 10.1038/ncomms14780.
[18] IBANEZ B, MACAYA C, SÁNCHEZ-BRUNETE V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction(METOCARD-CNIC)trial[J]. Circulation, 2013, 128(14): 1495-1503. DOI: 10.1161/circulationaha.113.003653.
[19] GRYGIER M, ARASZKIEWICZ A, LESIAK M, et al. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data[J]. Kardiol Pol, 2013, 71(2): 115-120. DOI: 10.5603/KP.2013.0002.
[20] NICCOLI G, SPAZIANI C, CREA F, et al. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial[J]. J Am Coll Cardiol, 2014, 63(14): 1454-1455. DOI: 10.1016/j.jacc.2013.10.042.
[21] ZHANG F, XUAN Y, CUI J, et al. Nicorandil modulated macrophages activation and polarization via NF-κb signaling pathway[J]. Mol Immunol, 2017, 88: 69-78. DOI: 10.1016/j.molimm.2017.06.019.
[22] FRACCAROLLO D, GALUPPO P, MOTSCHENBACHER S, et al. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition[J]. Basic Res Cardiol, 2014, 109(4): 421. DOI: 10.1007/s00395-014-0421-1.
[23] LI J Y, XU X M, ZHOU X B, et al. Cardiovascular events associated with nicorandil administration prior to primary percutaneous coronary intervention in patients with acute ST-segment elevated myocardial infarction: a systematic review and meta-analysis[J]. Expert Opin Drug Saf, 2019, 18(6): 537-547. DOI: 10.1080/14740338.2019.1617848.
[24] QIAN G, ZHANG Y, DONG W, et al. Effects of nicorandil administration on infarct size in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the CHANGE trial[J]. J Am Heart Assoc, 2022, 11(18): e026232. DOI: 10.1161/JAHA.122.026232.
[25] YU Y, YANG B P. Sodium nitroprusside injection immediately before balloon inflation during percutaneous coronary intervention[J]. World J Clin Cases, 2021, 9(36): 11248-11254. DOI: 10.12998/wjcc.v9.i36.11248.
[26] NAVARESE E P, FREDIANI L, KANDZARI D E, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: the RESTORE observational study[J]. Catheter Cardiovasc Interv, 2021, 97(4): 602-611. DOI: 10.1002/ccd.29113.
[27] DARWISH A, FRERE A F, ABDELSAMIE M, et al. Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study[J]. Ann Saudi Med, 2022, 42(2): 75-82. DOI: 10.5144/0256-4947.2022.75.
[28] VAN'T HOF A W J, HEESTERMANS T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty(On-TIME 2): a multicentre, double-blind, randomised controlled trial[J]. Lancet, 2008, 372(9638): 537-546. DOI: 10.1016/S0140-6736(08)61235-0.
[29] IBANEZ B, JAMES S, AGEWALL S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)[J]. Eur Heart J, 2018, 39(2): 119-177. DOI: 10.1093/eurheartj/ehx393.
[30] WANG L, CHENG Z, GU Y, et al. Short-term effects of verapamil and diltiazem in the treatment of No reflow phenomenon: a meta-analysis of randomized controlled trials[J]. Biomed Res Int, 2015, 2015: 382086. DOI: 10.1155/2015/382086.
[31] GARCÍA-MÉNDEZ R C, ALMEIDA-GUTIERREZ E, SERRANO-CUEVAS L, et al. Reduction of No reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute ST myocardial infarction[J]. Arch Med Res, 2018, 49(8): 620-629. DOI: 10.1016/j.arcmed.2018.10.006.
[32] XIANGREN A, LI Z A, LUO W, et al. Long-term compound Danshen dripping pills therapy reduces the no-reflow phenomenon in nondiabetes mellitus patients after primary percutaneous coronary intervention for acute myocardial infarction[J]. Ann Palliat Med, 2020, 9(3): 1144-1151. DOI: 10.21037/apm-20-1056.
[33] 贺娜,李敏娴,张旗,等.通心络胶囊对PCI术后无复流患者心肌微灌注的影响以及远期疗效与安全性[J].临床荟萃, 2021, 36(2): 129-133. DOI: 10.3969/j.issn.1004-583X.2021.02.007.
[34] 刘超,刘楠,吴航,等.利拉鲁肽对急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后无复流和心功能的影响[J].陕西医学杂志, 2022, 51(10): 1294-1297, 1312. DOI: 10.3969/j.issn.1000-7377.2022.10.029.
[35] NIU X W, ZHANG J J, BAI M, et al. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis[J]. BMC Cardiovasc Disord, 2018, 18(1): 3. DOI: 10.1186/s12872-017-0722-z.
[36] JOLLY S S, CAIRNS J A, YUSUF S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy[J]. N Engl J Med, 2015, 372(15): 1389-1398. DOI: 10.1056/nejmoa1415098.
[37] ANNIBALI G, SCROCCA I, ARANZULLA T C, et al. “No-reflow” phenomenon: a contemporary review[J]. J Clin Med, 2022, 11(8): 2233. DOI: 10.3390/jcm11082233.
[38] HIBI K, KOZUMA K, SONODA S, et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound[J]. JACC Cardiovasc Interv, 2018, 11(16): 1545-1555. DOI: 10.1016/j.jcin.2018.03.021.
[39] LUO D M, HU X M, SUN S, et al. The outcomes in STEMI patients with high thrombus burden treated by deferred versus immediate stent implantation in primary percutaneous coronary intervention: a prospective cohort study[J]. Ann Transl Med, 2021, 9(7): 573. DOI: 10.21037/atm-21-1130.
[40] MA M, WANG L, DIAO K Y, et al. A randomized controlled clinical trial of prolonged balloon inflation during stent deployment strategy in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a pilot study[J]. BMC Cardiovasc Disord, 2022, 22(1): 30. DOI: 10.1186/s12872-022-02477-0.
[41] ENGSTRØM T, KELBÆK H, HELQVIST S, et al. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a randomized clinical trial[J]. JAMA Cardiol, 2017, 2(5): 490-497. DOI: 10.1001/jamacardio.2017.0022.
[42] HAUSENLOY D J, KHARBANDA R K, MØLLER U K, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction(CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial[J]. Lancet, 2019, 394(10207): 1415-1424. DOI: 10.1016/S0140-6736(19)32039-2.
[43] DE MARIA G L, ALKHALIL M, BORLOTTI A, et al. Index of microcirculatory resistance-guided therapy with pressure-controlled intermittent coronary sinus occlusion improves coronary microvascular function and reduces infarct size in patients with ST-elevation myocardial infarction: the Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion study(OxAMI-PICSO study)[J]. EuroIntervention, 2018, 14(3): e352-e359. DOI: 10.4244/EIJ-D-18-00378.
[44] EGRED M, BAGNALL A, SPYRIDOPOULOS I, et al. Effect of Pressure-controlled intermittent Coronary Sinus Occlusion(PiCSO)on infarct size in anterior STEMI: PiCSO in ACS study[J]. Int J Cardiol Heart Vasc, 2020, 28: 100526. DOI: 10.1016/j.ijcha.2020.100526.